STOCK TITAN

Viatris to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Viatris Inc. (NASDAQ: VTRS) will announce its fourth quarter and full year 2022 financial results on February 27, before U.S. markets open. The announcement will be followed by a webcast at 8:30 a.m. ET on the same day, featuring insights from CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula. The public can access the live call through investor.viatris.com or by phone. Founded in November 2020, Viatris combines expertise in medicine distribution and sustainability, providing over 1,400 approved molecules in more than 165 countries.

Positive
  • None.
Negative
  • None.

PITTSBURGH, Feb. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to report its fourth quarter and full year 2022 financial results on Monday, February 27 before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on February 27 to discuss the results.

Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 866.342.8591 or 203.518.9713 for international callers (Conference ID: VTRSQ422).  A replay of the webcast also will be available on the website.

About Viatris 

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube

Viatris Logo (PRNewsfoto/Viatris Inc.)

 

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023-301747762.html

SOURCE Viatris Inc.

FAQ

When will Viatris report its fourth quarter and full year 2022 financial results?

Viatris will report its financial results on February 27, 2023.

What time is the Viatris financial results webcast scheduled for?

The webcast is scheduled for 8:30 a.m. ET on February 27, 2023.

How can I access the Viatris financial results call?

You can access the call at investor.viatris.com or by calling 866.342.8591 for domestic callers.

What is the significance of the financial results report for VTRS investors?

The financial results report is crucial for investors to assess the company's performance and future outlook.

Viatris Inc.

NASDAQ:VTRS

VTRS Rankings

VTRS Latest News

VTRS Stock Data

14.66B
1.19B
0.41%
82.85%
1.74%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
CANONSBURG